Related Experiment Video
Updated: Feb 21, 2026
10:28
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
10.3K
Recent Updates on Acquired Hepatocerebral Degeneration
Hae-Won Shin1,2, Hee Kyung Park3,4
1Department of Neurology, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Tremor and Other Hyperkinetic Movements (New York, N.Y.)
|October 5, 2017
Summary
Acquired hepatocerebral degeneration (AHD) involves toxic substance accumulation and neuroinflammation, causing neurological issues in liver disease patients. Neuroimaging reveals specific brain changes, aiding diagnosis of this complex syndrome.
Area of Science:
- Neurology
- Hepatology
- Radiology
Background:
- Acquired hepatocerebral degeneration (AHD) is a chronic neurological condition linked to advanced liver disease.
- It presents with diverse neurological symptoms and characteristic neuroimaging findings.
Purpose of the Study:
- To review the pathomechanism and neuroimaging findings in acquired hepatocerebral degeneration (AHD).
- To consolidate current understanding of this complex neurological syndrome.
Main Methods:
- A comprehensive literature search was conducted using PubMed.
- Keywords included "acquired hepatocerebral degeneration," "cirrhosis-related parkinsonism," and "manganese and liver disease."
Main Results:
- AHD pathogenesis involves toxic accumulation (ammonia, manganese) and neuroinflammation.
- Clinical features include parkinsonism, ataxia-plus syndrome, cognitive, and psychiatric impairments.
- Neuroimaging shows globus pallidus T1 hyperintensity in parkinsonism and cerebellar peduncle T2 lesions in ataxia-plus syndrome.
Conclusions:
- Further research is required to fully understand the heterogeneous mechanisms and neuroimaging characteristics of AHD.
- Elucidating these aspects will improve diagnosis and management of AHD.
Related Concept Videos
01:26Diseases of the Liver and Gallbladder
2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
01:26Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
225
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
225
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
299
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
299
01:24Liver Regeneration
4.5K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.5K
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K